Morgan's story began when he was taking an Uber ride in Nashville, chatting up his driver about songwriting. The newcomer had ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

JPMorgan Chase's co-head of global markets, Jason Sippel, is leaving the Wall Street lender and Pranav Thakur has been named ...

Belle da Costa Greene, who was JP Morgan’s librarian, became a lively fixture at Gilded Age mansions, country retreats, ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

JPMorgan Chase & Co. boosted its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) by 7,122.7% in the 3rd ...

The bank is sourcing compute resources five to 10 years out, said Darrin Alves, CIO of infrastructure platforms.

In the fast-paced world of investing, staying ahead requires good ideas and timely decisions. This article highlights five ...

Kaguya Komatsu has been named the first female CEO of J.P. Morgan Asset Management -Japan, succeeding Shoichi Ohkoshi, who ...

Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for ...

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, clinical-stage companies. But local biotech leaders see signs of change in ...